Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: lexi2004 who wrote (175475)	6/26/2008 9:19:04 AM
From: Findit	Read Replies (1) \| Respond to of 208838

You were just a tad faster than me. LOL. Congrats on your adds. Wish I had done the same. Jim

To: lexi2004 who wrote (175475)	6/26/2008 9:56:55 AM
From: Connor26	Read Replies (1) \| Respond to of 208838

bought a little AEHR here - any thougths or fibs on this one?

To: lexi2004 who wrote (175475)	6/26/2008 10:23:13 AM
From: presto	Read Replies (1) \| Respond to of 208838

NVAX for those that follow it. Novavax, Inc. (Nasdaq: NVAX) today announced that as of the close of the market Friday, June 27th, it will be included in the Russell 3000 Index, comprised of 3000 of the largest and most liquid stocks based and traded in the United States. Membership in the Russell 3000, which remains in place for a minimum of one year, means the common stock of Novavax will also be automatically included in the small cap Russell 2000 Index. The Russell 3000 Index is widely used by investment managers and institutional investors for Index funds and as benchmarks for both passive and active investments strategies. The Russell 3000 Index also serves as the U.S. component of the Russell Global Index. Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company creates VLPs by genetically engineering three-dimensional, nanostructures, which incorporate immunologically important lipids and recombinant proteins. Novavax' VLPs resemble a virus by lack the genetic material that would cause infection. Using the Company's proprietary virus-like particle (VLP) technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. The Company also utilizes a unique portable manufacturing system that allows for rapid production of vaccines requiring less infrastructure and represents a potential simpler and more efficient approach to vaccine production. Additional information about Novavax is available at novavax.com and in the Company's various filings with the Securities and Exchange Commission.